Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma A/S (ASND)
:ASND
ASND Analyst Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ASND Stock 12 Month Forecast
Average Price Target
$198.50
▲(27.97% Upside)
| Highest Price Target$289.00 | Average Price Target$198.50 | Lowest Price Target$162.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
02/19/25
Wells Fargo
Reiterated
02/18/25
Morgan Stanley
Reiterated
02/18/25
Wedbush
Reiterated
02/18/25
J.P. Morgan
Reiterated
02/13/25
Goldman Sachs
Reiterated
02/13/25
Evercore ISI
Reiterated
02/13/25
Stifel Nicolaus
Reiterated
02/13/25
Leerink Partners
Reiterated
02/12/25
TD Cowen
Reiterated
02/12/25
Cantor Fitzgerald
$170
Buy
9.60%
Upside
Reiterated
02/11/25
Cantor Fitzgerald reiterates Overweight Rating on Ascendis Pharma (ASND)Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ: ASND).
UBS
$196
Buy
26.36%
Upside
Initiated
01/07/25
Ascendis Pharma initiated with a Buy at UBSAscendis Pharma initiated with a Buy at UBS
Jefferies
$194
Buy
25.07%
Upside
Assigned
12/17/24
Ascendis Pharma (ASND) PT Raised to $194 at JefferiesJefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $194.00 (from $191.00) while maintaining a Buy rating.
Citi
$200
Buy
28.94%
Upside
Reiterated
12/16/24
Ascendis Pharma's Promising Growth Prospects: Buy Rating Backed by Positive Clinical Results and Expected Share Price Surge
Oppenheimer
$190→$180
Buy
16.05%
Upside
Reiterated
11/15/24
Ascendis Pharma (ASND) PT Lowered to $180 at OppenheimerOppenheimer analyst Leland Gershell lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $190.00) while maintaining a Outperform rating.
Best Analysts Covering Ascendis Pharma
Which Analyst Should I Follow If I Want to Buy ASND and Sell After:
1 Month
xxx
Success Rate
20/28 ratings generated profit
Average Return
+3.59%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +3.59% per trade.
3 Months
xxx
Success Rate
9/14 ratings generated profit
Average Return
+8.85%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +8.85% per trade.
1 Year
Success Rate
17/29 ratings generated profit
Average Return
+19.38%
reiterated a buy rating 9 days ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +19.38% per trade.
2 Years
xxx
Success Rate
16/23 ratings generated profit
Average Return
+16.99%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 69.57% of your transactions generating a profit, with an average return of +16.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ASND Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
11
14
8
11
10
Buy
25
29
17
21
22
Hold
10
10
13
15
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
53
38
47
46
Each month's total comprises the sum of three months' worth of ratings.
ASND Financial Forecast
ASND Stock Forecast FAQ
What is ASND’s average 12-month price target, according to analysts?
Based on analyst ratings, Ascendis Pharma A/S’s 12-month average price target is $198.50.
What is ASND’s upside potential, based on the analysts’ average price target?
Ascendis Pharma A/S has 27.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ASND a Buy, Sell or Hold?
Ascendis Pharma A/S has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
What is Ascendis Pharma A/S’s price target?
The average price target for Ascendis Pharma A/S is $198.50. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $289.00 ,the lowest forecast is $162.00. The average price target represents 27.97% Increase from the current price of $155.11.
The highest analyst price target is $289.00 ,the lowest forecast is $162.00. The average price target represents 27.97% Increase from the current price of $155.11.
What do analysts say about Ascendis Pharma A/S?
Ascendis Pharma A/S’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of ASND?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.